Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

Abstract

We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage IV malignant melanoma patients resistant to conventional therapies involving vaccination with mature dendritic cells (mDCs) combined with administration of low dose interleukin-2. Autologous monocytes were harvested from a single apheresis and cultured for 7 days… (More)

Topics

Cite this paper

@article{Nagayama2003ResultsOA, title={Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.}, author={Hitomi Nagayama and Katsuaki Sato and Mariko Morishita and Kaoru Uchimaru and Naoki Oyaizu and Takeshi Inazawa and Tomoko Yamasaki and Makoto Enomoto and Takashi Nakaoka and Tetsuya Nakamura and Taira Maekawa and Akifumi Yamamoto and Shinji Shimada and Toshiaki Saida and Y oshikazu Kawakami and Shigetaka Asano and Kenzaburo Tani and Tsuneo Takahashi and N. Yamashita}, journal={Melanoma research}, year={2003}, volume={13 5}, pages={521-30} }